image credit- shutterstock
Innovodigm, a Kolkata-based medtech startup revolutionising vaccine delivery through its proprietary needleless patch platform, has raised Rs 5.5 crore in a seed funding round led by the IAN Group.
The funding will accelerate the development and clinical readiness of the company’s patented Microneedle Array Patch (MAP), a painless, thermostable, and sharps-free vaccine delivery platform designed to address critical global immunisation gaps.
IAN contributed Rs 4.5 crore, with the remaining amount invested by PadUp Ventures. The company plans to utilise the funding for process optimisation, infrastructure scaling, and team expansion to support third-party preclinical validation and prepare for upcoming clinical trials.
Founded in 2020, Innovodigm is developing India’s first micro-array patch for vaccines, offering a transformative alternative to traditional injectable immunisations. Designed to overcome challenges such as cold-chain dependency, medical waste, and needle-stick injuries, the MAP uses thermostabilised vaccines that remain viable for up to 120 days at 40°C, eliminating the need for refrigeration and enabling outreach to remote, underserved areas.
The funding will be used to set up production facilities, strengthen the team, and complete testing with a leading vaccine manufacturer. Clinical trials are expected to begin next year.
The company has signed a Material Transfer Agreement (MTA) with a leading Indian vaccine manufacturer for third-party validation, with clinical trials scheduled to commence next year.
With plans to expand across India and other low- and middle-income countries, Innovodigm aims to adapt its patch for various vaccines, including measles, hepatitis, flu, and COVID-19 boosters. The company is also working on building local manufacturing hubs so that patches can be made closer to where they’re needed most.
